DeckTherapeutics awarded research grant for studies of THDG3 in higher animals
The rare pediatric disease hypoxic-ischemic encephalopathy (HIE) is caused by brain injury after oxygen deprivation during labor/delivery. HIE is a leading cause of neonatal mortality and of serious life-long disabilities such as cerebral palsy. It remains as a major healthcare challenge in industrialized countries and is an even larger burden in low-to-middle income countries.
The grant from the Bill & Melinda Gates Foundation will enable DeckTherapeutics to manufacture its omega-3 diglyceride IV emulsion THDG3 and have it tested in neonatal rat, lamb and piglet models of HIE at University Hospital Bonn, UC San Francisco and University College London, respectively.
The testing of THDG3 in both rodent and higher animal models of HIE will further strengthen DeckTherapeutics’ comprehensive preclinical data package and the company’s rationale for developing THDG3 as a first-in-class therapeutic for the orphan lead indication HIE.
Success of THDG3 in HIE will be a steppingstone to developing THDG3 for other conditions related to hypoxic-ischemic injury, such as adult ischemic stroke and myocardial infarction.